DESIGN, PATIENTS AND MEASUREMENTS: The presence of neuromuscular symptoms was ascertained by questionnaire in 33 consecutive patients with subclinical hypothyroidism (sHT) as compared to 44 age- and sex-matched controls. Blood was sampled for PTH, magnesium, phosphate, and total and ionized calcium determination. Patients reporting three or more symptoms were also studied by surface electromyography (sEMG). The study was repeated following a six-month L-T4 course. RESULTS: Neuromuscular symptoms were significantly more frequent in patients than in controls (P = 0. 0001), and correlated with TSH values (r = 0.52; P = 0.0001). Among patients showing three or more symptoms (n = 11), sEMG documented the presence of repetitive discharges in 8 patients. L-T4 therapy led to a significant improvement of symptoms (P = 0.0001); persistent repetitive discharges were no longer observed. Total and ionized calcium values, always within the normal limits, were significantly lower in patients than controls (P < 0.0001). An inverse relationship was observed between ionized calcium and: TSH values (r = -0.69, P = 0.0001); the number of neuromuscular symptoms (r = -0.53, P = 0.0001). L-T4 replacement induced a significant increase in both total and ionized calcium levels (P < 0.01 and P < 0.0001, respectively). CONCLUSIONS: Neuromuscular symptoms and dysfunction are rather common in subclinical hypothyroidism, and may be associated with abnormalities in serum calcium balance and surface electromyography. The ability of L-T4 treatment to reverse all these changes suggests that subclinical hypothyroidism patients may require early therapy not only to prevent progression to frank hypothyroidism, but also to improve their neuromuscular dysfunction.
DESIGN, PATIENTS AND MEASUREMENTS: The presence of neuromuscular symptoms was ascertained by questionnaire in 33 consecutive patients with subclinical hypothyroidism (sHT) as compared to 44 age- and sex-matched controls. Blood was sampled for PTH, magnesium, phosphate, and total and ionizedcalcium determination. Patients reporting three or more symptoms were also studied by surface electromyography (sEMG). The study was repeated following a six-month L-T4 course. RESULTS: Neuromuscular symptoms were significantly more frequent in patients than in controls (P = 0. 0001), and correlated with TSH values (r = 0.52; P = 0.0001). Among patients showing three or more symptoms (n = 11), sEMG documented the presence of repetitive discharges in 8 patients. L-T4 therapy led to a significant improvement of symptoms (P = 0.0001); persistent repetitive discharges were no longer observed. Total and ionizedcalcium values, always within the normal limits, were significantly lower in patients than controls (P < 0.0001). An inverse relationship was observed between ionizedcalcium and: TSH values (r = -0.69, P = 0.0001); the number of neuromuscular symptoms (r = -0.53, P = 0.0001). L-T4 replacement induced a significant increase in both total and ionizedcalcium levels (P < 0.01 and P < 0.0001, respectively). CONCLUSIONS: Neuromuscular symptoms and dysfunction are rather common in subclinical hypothyroidism, and may be associated with abnormalities in serum calcium balance and surface electromyography. The ability of L-T4 treatment to reverse all these changes suggests that subclinical hypothyroidismpatients may require early therapy not only to prevent progression to frank hypothyroidism, but also to improve their neuromuscular dysfunction.
Authors: Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka Journal: Thyroid Date: 2014-12 Impact factor: 6.568
Authors: L Bazzichi; A Rossi; C Zirafa; F Monzani; S Tognini; A Dardano; F Santini; M Tonacchera; M De Servi; C Giacomelli; F De Feo; M Doveri; G Massimetti; S Bombardieri Journal: Rheumatol Int Date: 2010-11-18 Impact factor: 2.631
Authors: P Rana; G Sripathy; A Varshney; P Kumar; M Memita Devi; R K Marwaha; R P Tripathi; S Khushu Journal: J Endocrinol Invest Date: 2011-04-20 Impact factor: 4.256
Authors: D Gallo; E Piantanida; G Veronesi; A Lai; L Sassi; V Lombardi; E Masiello; P Premoli; E Bianconi; C Cusini; S Rosetti; M L Tanda; A Toniolo; M Ferrario; L Bartalena Journal: J Endocrinol Invest Date: 2017-04-22 Impact factor: 4.256
Authors: A Tanriverdi; B Ozcan Kahraman; I Ozsoy; F Bayraktar; B Ozgen Saydam; S Acar; E Ozpelit; B Akdeniz; S Savci Journal: J Endocrinol Invest Date: 2018-11-19 Impact factor: 4.256
Authors: Vanessa S Virgini; Nicolas Rodondi; Peggy M Cawthon; Stephanie Litwack Harrison; Andrew R Hoffman; Eric S Orwoll; Kristine E Ensrud; Douglas C Bauer Journal: J Clin Endocrinol Metab Date: 2015-10-23 Impact factor: 5.958